Notably, higher SLC38A2 expression is associated with poor survival in lung cancer patients whose tumors exhibited SMARCA4 deletion, but not in patients whose tumors did not harbor SMARCA4 alterations (Fig. 5b). Here, SMARCA4 is linked to lung cancer.